Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | PPARA | Q07869 | 3/20 | 0.67 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.67 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.61 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.57 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.57 |
| ▸ | PPARD | Q03181 | 1/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27613074 | 0.98 | FFAR1 (0.69) | PPARGGAAPPARAFFAR1PLA2G4B | |
| SCHEMBL15981207 | 0.90 | PPARA (0.68) | PPARGGAAPPARAFFAR1PLA2G4B | |
| SCHEMBL4361279 | 0.88 | PLA2G4B (0.76) | PPARGFFAR1PLA2G4BSRD5A2S1PR1 | |
| SCHEMBL11485988 | 0.88 | PPARA (0.83) | PPARGGAAPPARASRD5A2LMNA | |
| SCHEMBL4561660 | 0.88 | GAA (0.79) | PPARGGAAPPARASRD5A2LMNA | |
| SCHEMBL14689477 | 0.86 | PPARA (0.81) | GAAPPARALMNAL3MBTL1MAPT | |
| SCHEMBL6652325 | 0.86 | PPARA (0.81) | GAAPPARALMNAL3MBTL1MAPT | |
| SCHEMBL20624042 | 0.86 | PPARA (0.81) | GAAPPARALMNAL3MBTL1MAPT | |
| SCHEMBL2127341 | 0.86 | PPARA (0.81) | GAAPPARALMNAL3MBTL1MAPT | |
| SCHEMBL2127003 | 0.86 | PPARA (0.81) | GAAPPARALMNAL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361668-B2 | Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors | UCB, S.A. (BE) | 2008-04-22 | — | — | US | disclosed |
| US-20050020660-A1 | Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors | UCB, S.A. (BE) | 2005-01-27 | — | — | US | disclosed |
| EP-1438309-A1 | QUINUCLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS M2 AND/OR M3 MUSCARINIC RECEPTOR INHIBITORS | UCB, S.A. (BE) | 2004-07-21 | — | — | EP | disclosed |
| WO-2003033495-A1 | QUINUCLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS M2 AND/OR M3 MUSCARINIC RECEPTOR INHIBITORS | UCB, S.A. (BE) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020660-A1 | Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors | CHRM2, CHRM3, CHRM1 | PPARG 521/4885GAA 1777/4885PPARA 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.